Radium-223 Superior to Strontium-89 for Prostate Cancer Bone Metastases – Renal and Urology News

Radium-223, an alpha emitter, but not strontium-89, a beta emitter, improves survival and decreases the risk of symptomatic skeletal events in patients with bone metastases from castration-resistant prostate cancer, a meta-analysis found.

Read the full article here

Related Articles